Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
Shockwave Medical, Inc. (Nasdaq: SWAV) will report its financial results for the fourth quarter and full year 2020 on February 17, 2021, after market close.
Rhea-AI Summary
Shockwave Medical, Inc. (Nasdaq: SWAV) will report its financial results for the fourth quarter and full year 2020 on February 17, 2021, after market close. A conference call for investors is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can participate via a domestic line at (866) 795-9106 or international line at (470) 495-9173, using conference ID: 7854854. The call will also be available through a live and archived webcast on the company's investor relations website.
Positive
- The company's focus on Intravascular Lithotripsy (IVL) positions it uniquely in the cardiovascular treatment market.
- IVL technology aims to improve patient outcomes and could establish a new standard of care.
Negative
- None.
Details
News Market Reaction – SWAV
In the trading session that priced this news, SWAV declined 6.81%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 17, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 7854854. A live and archived webcast of the event will be available at https://ir.shockwavemedical.com.
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.